Use of statins to prevent the recurrence of a heart attack after the first such incidence is a generally accepted practice guideline, but its effectiveness is muted because of nonadherence, according to a study in JAMA Cardiology.
The debate over just what a pharmaceutical company can say about off-label use of its medications pits free speech rights against the FDA’s mission to protect the public, STAT reports. A bill introduced by Rep. Morgan Griffith, a Virginia Republican, would make it easier for drugmakers to discuss new “intended uses” for some drugs.
Evidence-based interventions to improve adherence have become a focus of formulary decision makers. Regimen simplification works — up to a point. Once-daily dosing only slightly improves adherence compared with twice-daily dosing, according to study in Clinical Infectious Diseases.